Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare multisystem disease, characterized by thrombocytopenia, microangiopathic hemolytic anemia, neurologic abnormalities, renal abnormalities, and fever. [1] [2] [3] [4] However, only thrombocytopenia and microangiopathic hemolytic anemia are required for diagnosis. 3 Only 35% of patients have neurologic changes; these are subtle (i.e., headaches and confusion) and can easily be missed in neurosurgical patients with altered baseline levels of consciousness.
2,3
Generally, noncongenital TTP is secondary to autoantibody mediated reduction in activity of a disintegrin and metalloproteinase with thrombospondin domain 13 (ADAMTS 13), a metalloproteinase that degrades von Willebrand factor (vWF). 3, 5 Reduced vWF proteolysis results in platelet aggregation with consequent microvascular thrombosis, thrombocytopenia, and hemolytic anemia. 6 Although there have been case series of clopidogrel-associated TTP in the cardiac literature, there has been little discussion in the neurointerventional literature. We discuss a patient who likely developed TTP following clopidogrel administration after carotid artery stenting, along with its unique features.
Case Report
A middle-aged woman with untreated hypertension presented with altered mental status following an upper respiratory prodrome. She subsequently seized and became obtunded (Glasgow Coma Score 4T 
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Minessota, United States) placement from the cavernous to the distal cervical right ICA. Intraoperatively, the patient received heparin and abciximab. Postoperatively (hospital day [HD] 2), the patient was started on clopidogrel and aspirin (►Table 1). On HD 3, a bifrontal craniectomy was performed for cerebral edema. Clopidogrel was held on days 4 and 5 because of the craniectomy. On HD 6 the clopidogrel response time (P2Y12 reaction units [PRU] ) was nontherapeutic at 385; hence she was reloaded. Subsequent clopidogrel dosing was based on daily PRU measurements. On HD 9, her PRU decreased to 178 (therapeutic range < 194) so she was maintained on 75 mg clopidogrel daily. Clopidogrel was stopped after administration on HD 10 because of new profound thrombocytopenia with a platelet count of 46,000/μL with subsequent nadir to 3,000/μL (►Fig. 1). Petechial rash was noted on both arms. Four platelet pheresis units were transfused that day, with an increase of platelets to 15k/μL. Hemoglobin decreased to 6.3 g/ dl (from 8.3 g/dL on HD 9). Hence she was transfused 3 units of packed red blood cells.
Hematologic work-up demonstrated occasional schistocytes. Mildly increased lactate dehydrogenase, alanine transferase, and aspartate aminotransferase levels were noted. Haptoglobin and D-dimer levels were elevated. Total and indirect bilirubin, international normalized ratio, partial thromboplastin time, and fibrinogen levels were within normal limits. Serum creatinine level remained within normal limits. Her maximum temperature was 40.1°C on HD 10. Her neurologic status was unchanged. Given subsequent concern for TTP, an ADAMTS13 level was sent; it was normal. Her Rose and Eldor score was 6, consistent with severe TTP. Intravenous methylprednisolone was started on HD 10 and gradually tapered off. Therapeutic plasma exchange (TPE) was begun on HD 11 and performed daily until HD 15. Her platelet counts increased from 47,000/μL after TPE on HD 11 to 242,000/μL on HD 15. Aspirin was resumed on HD 15. Her neurologic status remained unchanged.
Discussion
Following carotid and coronary artery stenting, thienopyridines and aspirin are prescribed to reduce the rate of stent thrombosis and consequent major complications.
7-9 All three thienopyridines (ticlopidine, clopidogrel, and prasugrel) have been linked to TTP. Ticlopidine has the highest reported incidence of TTP at 1 case per 1,600 to 5,000 treated patients. 6, 10 Clopidogrel-mediated TTP is rare, with 11 cases reported among 3 million patients between 1998 and 2001 and 197 reported cases by 2011. 4, 10 As noted in our patient, clopidogrel-associated TTP generally occurs within 2 weeks of therapy. 4 In early thienopyridine-associated TTP (< 2 weeks), the mechanism is not known but involves microvascular endothelial cell damage. 6 The mechanism may be nonimmunologic because no antibodies to ADAMTS13 have been reported in clopidogrel-associated TTP compared with 100% ADAMSTS13 activity deficiency has only been reported in a minority (0-22%) of clopidogrel-associated TTP cases compared with severe deficiency in 80 to 100% of ticlopidineinduced TTP and virtually all cases of idiopathic TTP.
3,5,10,11
Hence clopidogrel-associated TTP appears to be primarily a clinical diagnosis. To this end, the Rose and Eldor scoring system, based on platelet count, hemoglobin, serum creatinine, and neurologic function, has been used to assess the likelihood of TTP; a score 4 of 8 indicates a high probability of TTP.
1,4
Given the highly thrombogenic nature of the Pipeline devices, as used in this case, antiplatelet therapy was guided by PRU. Because clopidogrel is a prodrug and patients are variably responsive, reloading may be performed. It has been shown to overcome platelet nonresponsiveness, with reduced rates of myocardial infarction, stent thrombosis, and cardiovascular death following cardiac stenting.
12-14
Management recommendations for clopidogrel-associated TTP are based on case reports. Clopidogrel should be discontinued. The role of TPE is unclear. Unlike cases of thienopyridineassociated TTP occurring after 2 weeks of therapy, where TPE dramatically improves survival (84% versus 38%), in patients treated with clopidogrel for < 14 days who had TTP (n ¼ 26), survival was 70% with TPE and 66.7% without TPE.
11 Additional recommendations that are not specific to early thienopyridineassociated TTP include (1) continue TPE for at least 2 days after platelet count > 150k/μL; (2) avoid platelet transfusion in the absence of life-threatening bleeding; (3) administer high-dose steroids and folic acid; (4) consider aspirin and prophylactic dose low-molecular-weight heparin when platelet count is > 50k/μL; (5) PRBC transfusion as needed; and (6) advise patients of possibility of relapse.
2-4

Conclusions
Clopidogrel-associated TTP generally occurs within 2 weeks of the initial dose of clopidogrel. Because there is frequently no ADAMTS13 activity deficiency, diagnosis is primarily clinical, such as the Rose and Eldor score. Management is largely based on case reports. To our knowledge, this phenomenon has not been described in the neurocritical care literature. Given the frequency of neurointerventional endovascular procedures and the consequent need for dual antiplatelet therapy, this uncommon side effect must be recognized.
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